Truist Financial Maintains RadNet(RDNT.US) With Buy Rating, Announces Target Price $74
Jefferies Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $77
Raymond James Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $66
Truist Financial Maintains RadNet(RDNT.US) With Buy Rating
Radnet (RDNT) Receives a Buy From Truist Financial
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), CSL (OtherCMXHF) and BioMarin Pharmaceutical (BMRN)
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Maintains Target Price $60
Truist Financial Maintains RadNet(RDNT.US) With Buy Rating
Analysts' Top Healthcare Picks: Radnet (RDNT), Immunic (IMUX)
Marie Thibault's Buy Rating on ICAD: Attractive Valuation and Synergistic Potential With RadNet
Truist Financial Maintains RadNet(RDNT.US) With Buy Rating, Announces Target Price $74
Truist Securities Maintains Buy on RadNet, Lowers Price Target to $74
RadNet Analyst Ratings
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Maintains Target Price $60
RadNet Price Target Cut to $60.00/Share From $74.00 by Barclays
RadNet Is Maintained at Overweight by Barclays
RadNet Analyst Ratings
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Cuts Target Price to $60
Radnet (RDNT) Receives a Buy From Barclays